Sanofi Announces Study Program Evaluating Toujeo® in a Real-Life Setting

− Study program to investigate patient experience and clinical effectiveness in people with type 2 diabetes −

Paris, France – June 4, 2015 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today a program of Phase IV clinical trials to study Toujeo® (insulin glargine [rDNA origin] injection, 300 units per mL) in ‘real-world’ conditions. The Real Life Study program in people with type 2 diabetes comprises the ACHIEVE CONTROL, REACH CONTROL and REGAIN CONTROL studies and will compare the clinical effectiveness of Toujeo® with other basal insulins in a standard care setting, along with additional measures relating to patient experience and health resource utilization.

“There is a need to go beyond drug comparison and move toward investigation of wider diabetes management strategies, where additional factors are considered,” commented Riccardo Perfetti, Senior Medical Officer, Vice President Global Medical Affairs, Diabetes Division, Sanofi. “This study program will evaluate how the safety and efficacy findings for Toujeo® seen in the EDITION studies might now translate into real-life effectiveness in the treatment of adults with type 2 diabetes.”

The research program will involve more than 4,500 adults with type 2 diabetes from the U.S. and Europe. It will investigate control of blood sugar levels, incidence of hypoglycemia, persistence with treatment, patient-reported outcomes and health resource usage, with Toujeo® and other basal insulins as used in the standard care setting.

The ACHIEVE CONTROL study will evaluate the effect of Toujeo® on achieving individualized glycemic targets without hypoglycemia at any time of day in 3,270 uncontrolled insulin-naïve people in the U.S. with type 2 diabetes. REACH CONTROL will follow 800 insulin-naïve people with type 2 diabetes in Europe, comparing HbA1c change with Toujeo® vs. other basal insulins, alongside incidence of hypoglycemia, change in body weight, and measures of persistence with treatment and need for treatment intensification. The REGAIN CONTROL study will compare HbA1c reduction, incidence of hypoglycemia, change in body weight and persistence with treatment on Toujeo® vs. other basal insulins in 600 people with type 2 diabetes in Europe, who are currently uncontrolled on basal insulin. In addition to clinical measures, the studies will also collect patient feedback on treatment satisfaction and their experience of hypoglycemia, along with healthcare resource utilization.

The studies are expected to begin randomizing patients in Q2 2015, with initial results expected in 2017. Results from an extended follow-up period are anticipated in 2018.

“While randomized controlled trials establish the efficacy and safety profile in a defined population and address regulatory needs, healthcare professionals, diabetes educators and payers may find real-world evidence provides important value to the management of diabetes,” said Luigi Meneghini, MD, MBA, Professor of Internal Medicine at the University of Texas Southwestern Medical Center, Division of Endocrinology, Dallas, Texas, and Principal Investigator of the ACHIEVE CONTROL study. “This program of research is a step forward in meeting this need, evaluating the use of Toujeo® and other basal insulins in a real life setting.”

About Toujeo®

Despite basal insulin being a cornerstone treatment for diabetes for decades, significant unmet medical needs remain a reality, with approximately half of patients on treatment not reaching their blood sugar level targets.1-6 In addition, optimal insulin dose is often not reached during initiation or maintenance phase. Toujeo® is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile.7 Its compact subcutaneous depot leads to more stable and more prolonged pharmacokinetic / pharmacodynamic (PK/PD) profiles.8-10 Toujeo® has been approved by the U.S. Food and Drug Administration (FDA), the European Commission and Health Canada, and is under review by other regulatory authorities around the world.

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets injectable, inhaled and oral medications for people with type 1 or type 2 diabetes.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


  1. Banegas JR, López-García E, Dallongeville J, et al. Eur Heart J. 2011;32(17):2143-52, DOI: 10.1093/eurheartj/ehr080.
  2. Stark Casagrande S, Fradkin JE, Saydah SH, et al. Diabetes Care. 2013;36(8):2271-9, DOI: 10.2337/dc12-2258.
  3. Chan JCN, Gagliardino JJ, Baik SH, et al. Diabetes Care. 2009;32(2):227-33, DOI: 10.2337/dc08-0435.
  4. Choi YJ, Kim HC, Kim HM, et al. Diabetes Care. 2009;32(11):2016-20, DOI: 10.2337/dc08-2228.
  5. Steinberg BA, Bhatt DL, Mehta S, et al. American Heart Journal. 2008;156(4):719-27, DOI: 10.1016/j.ahj.2008.05.020.
  6. Vouri SM, Shaw RF, Waterbury NV, et al. Journal of Managed Care Pharmacy : JMCP. 2011;17(4):304-12,
  7. Gerstein HC, Bosch J, Dagenais GR, et al. The New England Journal of Medicine. 2012;367(4):319-28, DOI: 10.1056/NEJMoa1203858.
  8. Steinstraesser A, Schmidt R, Bergmann K, et al. Diabetes, Obesity and Metabolism. 2014;16(9):873-6, DOI: 10.1111/dom.12283.
  9. Becker RHA, Dahmen R, Bergmann K, et al. Diabetes Care. 2015;38(4):637-43, DOI: 10.2337/dc14-0006.
  10. Shiramoto M, Eto T, Irie S, et al. Diabetes, Obesity and Metabolism. 2014:epub ahead of print, DOI: 10.1111/dom.12415.

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Media Relations     Investor Relations
Jack Cox  Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
Global Diabetes Communications US Diabetes Communications
Tilmann Kiessling Susan Brooks
Mobile: +(49) 17 26 15 92 91 Tel : +(1) 908-981-6566